PF-Atlas › Clinical Trials › NCT04619680
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Nintedanib · Phase 4
Registry ID
NCT04619680
Phase
Phase 4
Status
Completed
Drug / intervention
Nintedanib
Sponsor
Icahn School of Medicine at Mount Sinai
Start
2020-11-18
About this trial
Nintedanib is evaluated in NCT04619680, a Phase 4 idiopathic pulmonary fibrosis study sponsored by Icahn School of Medicine at Mount Sinai. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT04619680 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.